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modalities, namely CT and MRI. Potential prognostic factors 
in survival were evaluated in the univariate analysis that 
multivariate analysis.  
 
Results: An objective clinical response (ie clinical 
improvement) was observed in 24% of patients. Of the 
evaluable patients, almost one third showed a complete 
radiological response (8%) or partial (22%). The median 
overall survival (OS) and progression-free survival (PFS) after 
retreatment were 10.9 and 8.6 months, respectively. By 
multivariate analysis, we have identified four independent 
prognostic factors for survival: (1), the first perfomance 
status of reprocessing (P = 0.002), (2), the duration of the 
interval between treatments (P 0.008) (three), histology of 
the tumor and (4), the response to initial treatment (P 
values, 0.04). The median survival for patients with 
perfomance status = 0-1 and <2 was of 14.0 and 7.4 months, 
respectively. Patients with oligodendrogliomas showed a 
median OS of 27.5 months while patients with astrocytoma 
had a median OS of 6.9 months after retreatment. There 
were no long-term complications of reprocessing. Quality of 
life after reprocessing and to clinical progression, however, 
was good: all patients remained able to ambulate 
independently and were able to take care of itself. 
 
Conclusion: Re-irradiation in selected patients with relapsed 
brain tumors seems feasible option. 
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Purpose or Objective: Whole brain radiotherapy is the 
standard treatment after resection of brain metastases 
however due to its neurotoxicity some other treatments such 
as stereotactic radiotherapy are under investigation. Our 
purpose is to evaluate the acute toxicity and efficacy of 
postoperative hypofractionated stereotactic radiotherapy to 
the resection cavity in brain metastasis. 
 
Material and Methods: From october 2011 to september 
2015, we treated and analyzed 20 patients diagnosed with 
intracranial metastasis who were treated by resection 
followed by postoperative hypofractonated stereotactic 
radiotherapy. All treatment decisions were based on a 
multidisciplinary approach, all patients signed consent form 
before treatment. In all cases countouring was based on MRI 
and CT fused images, and three different fractionation 
schemes were used : 7 x5 Gy (n=10), 5x6Gy(n=7) and 10x4Gy 
(n=3). Treatment has been performed using the Novalis 
ExacTrac image guided system which consists of a non 
invasive frame-based mask system that allows us to perform 
stereotactic treatments. Treatment plan was performed on 
Iplan-net (v. 4.1) with either multiple non coplanar 
conformal beams or dynamic conformal arcs, using 
3Dconformal radiation therapy or IMRT if it was needed. On 
treatment room the Novalis IGRT is based on two X-ray 
orthogonal images that fuse bone structures with DRR 
reconstructed from CT simulation scan. A Robotic 6D coach 
corrects with submillimeter accuracy translational both and 
rotational errors before treatment.  
 
Results: The median age was 57 years. Seven patients were 
male and 13 female. The most frecuent primary tumor was 
lung in 65%, followed by breast in 25%, and ovary and 
hepatocarcinoma in 5%. All the patients received treatment 
with desxametasone during the treatment and maintained it 
for at least two weeks after the treatment completion. 85% 
of patients remained asymptomatic during treatment. 15% 
had grade I toxicity. Local control was achieved in 85% of 
patients with a median follow up of 13 months. Intracranial 
median free survival was 11,9 months. Median survival time 
was 12 months (range 1- 34months). 30% had new brain 
metastases who were treated with whole-brain radiation 
therapy or radiosurgery.  
 
Conclusion: Stereotactic hypofractionated radiotherapy after 
resection brain metastasis seems feasible and well tolerated. 
No significant toxicity was observed. Whole brain 
radiotherapy can be reserved in cases of progression. 
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Purpose or Objective: Medulloblastoma and central nervous 
system PNET are rare primary brain tumors in adults. The 
role of chemotherapy as a part of standard treatment in 
adult patients is not defined. We aimed to evaluate the 
toxicity and early results of combined treatment: surgery, 
multiagent chemotherapy followed by craniospinal irradiation 
in adult patient. 
 
Material and Methods: From January 2011 to December 
2014, 13 adult patients:6 women and 7 men, with 
medulloblastoma or PNET were treated. Median age was 30,4 
years (20,8-46,7). All patients underwent surgery. There 
were five PNET and eight medulloblastomas, including 
desmoplastic variant in 2 pts, anaplastic in 1 pt, nodularis in 
2 pts and the no specific type in remaining. Neuraxis MRI 
performed after surgery showed active tumor and spinal 
metastases in three pts, tumor in operated site in 5 and no 
signs of disease in 5 pts. There were 6 standard and 7 high 
risk patients. All patients were treated with multiagent 
chemotherapy including cisplatin, cyclophosphamide, 
etoposide and vincristine and received G-CSF as a primary 
prevention of febrile neutropenia. After chemotherapy the 
craniospinal irradiation was performed using conformal 
radiotherapy (8 pts) or tomotherapy (5 pts) with the mean 
dose 32,7 Gy (14,4-36 Gy) to the craniospinal axis and mean 
boost dose of 18,8Gy (18-23,4 Gy) to the primary tumor 
location. MRIs were performed after treatment to monitor 
response. All patients completed the whole protocol. 
 
Results: Ten patients received 2 courses, 2 patients 3 courses 
and one patient received only one course of chemotherapy. 
Chemotherapy was given on time. The hematological toxicity 
of chemotherapy was: neutropenia WHO IV in 2 and WHO III 
in 4 pts after the first course and WHO IV in 4 and WHO III in 
3 pts after the second course of chemotherapy. There was no 
febrile neutropenia. Radiological complete and partial 
response were recorded in 2 and 4 pts respectively in those 
with previous active disease. Two patients progressed while 
waiting for radiotherapy. Mean time of radiotherapy was 1,6 
mo. During radiotherapy hematological toxicity was 
observed: leucopenia – WHO II in 5 pts that started in second 
week of irradiation and WHO III in 2 pts in the third and forth 
week, thrombocytopenia - WHO I in 5 pts, WHO II in 3 pts and 
WHO III in one. Five patients required treatment 
interruptions with median duration of 12 days. Median overall 
treatment time was 6,4 mo. Median follow up was 17,9 mo. 
Six patients relapsed after median time of 13,1 mo, four of 
them locally and two disseminated via cerebral fluid. Five 
patients died in spite of salvage treatment. Median time of 
DFS and OS were 13,3 mo and 17,9 mo respectively. One and 
2 year OS and DFS are 92% and 45% and 68% and 42% 
respectively.  
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Conclusion: Sequential chemotherapy and radiotherapy in 
adult medulloblastoma/PNET tumors is feasible with 
acceptable toxicity. High relapse rate in our patients indicate 
the need of treatment intensification with better 
coordination of combined therapy. 
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Purpose or Objective: Glioma is a primary brain tumour 
arising from the glial cells. High grade glioma, defined as 
grade III and IV, have poor survival rates. Glioblastoma 
multiforme is the commonest, but is also, the most 
aggressive type of glioma and is associated with a poor 
prognosis. Median survival of patients after treatment with 
debulking surgery followed by concurrent chemoradiotherapy 
and adjuvant chemotherapy is 14.6 months. Currently, post-
operative fractionated radiotherapy is prescribed to a range 
of 54 to 60 Gy in fractions of 2 Gy.  
Organs at risk (OARs) including optic chiasm, optic nerves and 
the brain stem, may lie within, or in close proximity to the 
PTV. Neuropathy and/or necrosis has been shown to occur 
when the maximum dose exceeds 55Gy in the optic chiasm 
and 54Gy to the whole brainstem. The standard practice at 
Rosemere Cancer Centre is to prioritise the OARs at the 
expense of the total dose, therefore prescribing to a dose of 
54Gy whenever the OARs is included in the PTV, which may 
have repercussions on tumour control and ultimately, overall 
survival.  
This retrospective analysis aims to compare patient outcomes 
between the 54Gy/57Gy and 59.4Gy/60Gy regimes, to 
determine if compromising the dose to spare OARs is 
detrimental to tumour control and survival. 
 
Material and Methods: The data of all glioma patients 
treated with radiotherapy between December 2012 and 
December 2014 at Rosemere Cancer Centre, were collected 
from our electronic databases. A total of 167 patients were 
identified. Patients with low grade glioma and those treated 
with a palliative intent were excluded. Fifty eight patients 
were included in the analysis. 
 
Results: Twenty one patients were on a lower dose 
radiotherapy regime of 54Gy or 57Gy. The remaining 37 were 
on a higher dose regime of 59.4Gy or 60Gy. There was a 
statistically significant difference (p=0.05) in patients treated 
with the higher dose regime comparatively, of an additional 
7.2 months median overall survival (mOS) benefit. The 
mortality hazard for the higher dose regime is 37% lower than 
the lower dose regime. 
 
Conclusion: The outcome of patients treated with the 
59.4/60Gy dose regime has shown to be statistically 
significant with a mOS benefit and lower mortality hazard. It 
is therefore clear that maintenance of the higher dose 
(59.4/60Gy) should be a priority, either at the expense of the 
OARs or to as much of the tumour volume as possible, whilst 
still observing the OARs constraints. 
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Purpose or Objective: Collateral irradiation of normal 
structures during whole brain radiotherapy increases the risk 
of secondary toxicities, including dysfunction of the 
hypothalamic-pituitary axis (HPA). In studies of children 
treated for intracranial neoplasms, Merchant et al. showed 
that upwards of 66% of patients had pre-irradiation 
endocrinopathies and that HPA dosimetry data can be used to 
predict the dose-volume effects of radiation on growth 
hormone (GH) secretion. However, no comparable endocrine 
studies have been performed in adult populations. Evidence 
exists to suggest that hypopituitarism is an independent risk 
factor for mortality in adults treated with whole brain 
radiotherapy. Increased collaboration between radiation 
oncologists and endocrinologists is needed to amalgamate 
dosimetry data with the results of endocrine testing and 
better characterize HPA dysfunction. The purpose of this 
study is to determine the presence of baseline HPA 
dysfunction as well as the time to onset and dose-
dependence of post-irradiation HPA dysfunction in adults 
treated for non-pituitary brain tumours. 
 
Material and Methods: Twelve patients, 3 males and 9 
females, have been enrolled in our prospective clinical study 
that will continue to recruit until 2017. Primary diagnoses 
included meningioma (7), pineal tumor (3), and glioma (2). 
Median patient age is 52 (range 23-71). Enrolled patients 
have undergone comprehensive baseline endocrine testing of 
the thyroid, gonadotropins, cortisol, prolactin, and GH prior 
to initiation of radiotherapy. Patients have received daily 
image guidance imaging with positional correction and 50-60 
Gy of radiation to the tumour bed. Parametisation of 
available dosimetry data was performed to determine the 
maximum, minimum, and mean radiation doses. Endocrine 
testing is being repeated at 6 month intervals following 
radiotherapy. Patient reported outcome measures are also 
collected during follow-up encounters. Reviewing 
endocrinologists have been blinded to dosimetry data. 
 
Results: Three patients (25%) demonstrated pre-irradiation 
endocrinopathies, including 2 cases of primary 
hypothyroidism and 1 case of primary hypogonadism. 
Furthermore, one patient exhibited temporary HPA 
suppression secondary to exogenous steroid use. Median 
length to endocrinology follow-up is still short at only 3 
months (range 0-18). We present analyzed dose data for 10 of 
the 12 patients. Mean radiation doses to the hypothalamus 
and pituitary were 35 Gy (range 20-55) and 31 Gy (range 13-
50), respectively. No cases of new, radiation-related HPA 
dysfunction have been identified to date. 
 
Conclusion: The incidence of pre-irradiation HPA dysfunction 
underlines the need for baseline endocrinology studies. The 
range of radiation doses to the HPA should allow for 
identification of dose-volume responses.  
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Purpose or Objective: Present and retrospectively evaluate 
our protocol of WBRT + SIB regarding radiation-induced 
alopecia 
 
Material and Methods: We use masks type 35764 / 2MA / M 
Orfit a subnet mask with eXaskin and compatible base 
resonance (eXaFrame). A similar number of slices is used in 
the images of CT and MRI, both acquisitions with identical 
position and immobilization and slice thickness of 1 mm. This 
is possible thanks to eXaFrame, resulting in excellent quality 
